Biome Australia expects to surpass its upgraded revenue forecast of $12.5 million for FY24, buoyed by strong sales revenues in April and May.

The company originally forecasted $11.5 million, later revising to $12.5 million.

The company also anticipates reporting a second consecutive quarter of positive underlying operating cash flow and EBITDA for the fourth quarter of FY24.

Biome Australia is also preparing to launch its Biome Cholesterol Probiotic in the first quarter of FY25.

Clinical trials have shown that the product can reduce cholesterol levels by 14% over a 12-week period, contributing to the company's mission to improve health outcomes for patients.